{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T04:17:24Z","timestamp":1769573844663,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NO. 82400238"],"award-info":[{"award-number":["NO. 82400238"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Jiangxi Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["No. 20224BAB216062"],"award-info":[{"award-number":["No. 20224BAB216062"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Jiangxi Provincial Health Technology Project","award":["No. 202410140"],"award-info":[{"award-number":["No. 202410140"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["CIFMS\uff1a2021-I2M-1-041"],"award-info":[{"award-number":["CIFMS\uff1a2021-I2M-1-041"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-025-04212-w","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T12:27:34Z","timestamp":1739363254000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Construction of\u00a0tetravalent bispecific Tandab (CD3\/BCMA)-secreting human umbilical cord mesenchymal stem cells and its efficiency in the treatment of\u00a0multiple myeloma"],"prefix":"10.1186","volume":"16","author":[{"given":"Mengshang","family":"Xiong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunfang","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaojun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weirong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixia","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiling","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liting","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6653-3232","authenticated-orcid":false,"given":"Caishui","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"issue":"1","key":"4212_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"4212_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1001\/jama.2021.25306","volume":"327","author":"J Silberstein","year":"2022","unstructured":"Silberstein J, Tuchman S, Grant SJ. What Is Multiple Myeloma? JAMA. 2022;327(5):497.","journal-title":"JAMA"},{"issue":"9983","key":"4212_CR3","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig C, Knop S, Bornh\u00e4user M. Multiple myeloma. Lancet Lond Engl. 2015;385(9983):2197\u2013208.","journal-title":"Lancet Lond Engl"},{"issue":"6","key":"4212_CR4","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.3390\/cancers15061819","volume":"15","author":"D Swan","year":"2023","unstructured":"Swan D, Murphy P, Glavey S, Quinn J. Bispecific antibodies in multiple myeloma: opportunities to enhance efficacy and improve safety. Cancers Basel. 2023;15(6):1819.","journal-title":"Cancers Basel."},{"issue":"1","key":"4212_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","volume":"14","author":"Z Tian","year":"2021","unstructured":"Tian Z, Liu M, Zhang Y, Wang X. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol OncolJ Hematol Oncol. 2021May 3;14(1):75.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"18","key":"4212_CR6","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","volume":"21","author":"D Przepiorka","year":"2015","unstructured":"Przepiorka D, Ko CW, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu HJ, et al. FDA approval: blinatumomab. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21(18):4035\u20139.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"14","key":"4212_CR7","doi-asserted-by":"publisher","first-page":"7652","DOI":"10.3390\/ijms22147652","volume":"22","author":"M Cosenza","year":"2021","unstructured":"Cosenza M, Sacchi S, Pozzi S. Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment. Int J Mol Sci. 2021;22(14):7652.","journal-title":"Int J Mol Sci"},{"issue":"22","key":"4212_CR8","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1182\/bloodadvances.2018020198","volume":"2","author":"T Jain","year":"2018","unstructured":"Jain T, Litzow MR. No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Blood Adv. 2018;2(22):3393\u2013403.","journal-title":"Blood Adv"},{"key":"4212_CR9","doi-asserted-by":"crossref","unstructured":"Abstract 55: Generation of half-life extended anti-CD33 BiTE\u00ae antibody constructs compatible with once-weekly dosing | Cancer Research | American Association for Cancer Research [Internet]. [cited 2024 Sep 25]. Available from: https:\/\/aacrjournals.org\/cancerres\/article\/77\/13_Supplement\/55\/621265\/Abstract-55-Generation-of-half-life-extended-anti","DOI":"10.1158\/1538-7445.AM2017-55"},{"issue":"1","key":"4212_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/gt.2011.68","volume":"19","author":"L Sanz","year":"2012","unstructured":"Sanz L, Compte M, Guijarro-Mu\u00f1oz I, \u00c1lvarez-Vallina L. Non-hematopoietic stem cells as factories for in vivo therapeutic protein production. Gene Ther. 2012;19(1):1\u20137.","journal-title":"Gene Ther"},{"issue":"9","key":"4212_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.73","volume":"5","author":"R Aliperta","year":"2015","unstructured":"Aliperta R, Cartellieri M, Feldmann A, Arndt C, Koristka S, Michalk I, et al. Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts. Blood Cancer J. 2015;5(9): e348.","journal-title":"Blood Cancer J"},{"issue":"2","key":"4212_CR12","doi-asserted-by":"publisher","first-page":"797","DOI":"10.4143\/crt.2018.364","volume":"51","author":"JR Heo","year":"2019","unstructured":"Heo JR, Hwang KA, Kim SU, Choi KC. A potential therapy using engineered stem cells prevented malignant melanoma in cellular and xenograft mouse models. Cancer Res Treat. 2019;51(2):797\u2013811.","journal-title":"Cancer Res Treat"},{"issue":"6","key":"4212_CR13","doi-asserted-by":"publisher","first-page":"11692","DOI":"10.3390\/ijms140611692","volume":"14","author":"DW Kim","year":"2013","unstructured":"Kim DW, Staples M, Shinozuka K, Pantcheva P, Kang SD, Borlongan CV. Wharton\u2019s jelly-derived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications. Int J Mol Sci. 2013;14(6):11692\u2013712.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4212_CR14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/CJI.0000000000000401","volume":"45","author":"M Xiong","year":"2022","unstructured":"Xiong M, Liu R, Lei X, Fan D, Lin F, Hao W, et al. A novel CD3\/BCMA bispecific T-cell redirecting antibody for the treatment of multiple myeloma. J Immunother. 2022;45(2):78\u201388.","journal-title":"J Immunother"},{"issue":"23","key":"4212_CR15","first-page":"1987","volume":"118","author":"L Ma","year":"2005","unstructured":"Ma L, Yong FX, Lin CB, Law F, Wu JX, Yang LY, et al. Human umbilical cord Wharton\u2019s Jelly-derived mesenchymal stem cells differentiation into nerve-like cells. Chin Med J (Engl). 2005;118(23):1987\u201393.","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"4212_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s43018-023-00516-z","volume":"4","author":"S Zinn","year":"2023","unstructured":"Zinn S, Vazquez-Lombardi R, Zimmermann C, Sapra P, Jermutus L, Christ D. Advances in antibody-based therapy in oncology. Nat Cancer. 2023;4(2):165\u201380.","journal-title":"Nat Cancer"},{"issue":"2","key":"4212_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10549-006-9449-8","volume":"105","author":"MA Stoff-Khalili","year":"2007","unstructured":"Stoff-Khalili MA, Rivera AA, Mathis JM, Banerjee NS, Moon AS, Hess A, et al. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat. 2007;105(2):157\u201367.","journal-title":"Breast Cancer Res Treat"},{"issue":"23","key":"4212_CR18","doi-asserted-by":"publisher","first-page":"9614","DOI":"10.1158\/0008-5472.CAN-08-0451","volume":"68","author":"K Sm","year":"2008","unstructured":"Sm K, Jy L, Si P, Ch J, Jh O, et al. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Cancer Res [Internet]. 2008;68(23):9614.","journal-title":"Cancer Res [Internet]."},{"issue":"2","key":"4212_CR19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/stem.1271","volume":"31","author":"J Nystedt","year":"2013","unstructured":"Nystedt J, Anderson H, Tikkanen J, Pietila M, Hirvonen T, Takalo R, et al. Cell surface structures influence lung clearance rate of systemically infused mesenchymal stromal cells. Stem cells. 2013;31(2):317\u201326.","journal-title":"Stem cells"},{"issue":"8","key":"4212_CR20","doi-asserted-by":"publisher","first-page":"997","DOI":"10.4155\/tde.12.69","volume":"3","author":"SJ Greco","year":"2012","unstructured":"Greco SJ, Rameshwar P. Mesenchymal stem cells in drug\/gene delivery: implications for cell therapy. Ther Deliv. 2012;3(8):997\u20131004.","journal-title":"Ther Deliv"},{"issue":"10","key":"4212_CR21","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1002\/stem.187","volume":"27","author":"S Kidd","year":"2009","unstructured":"Kidd S, Spaeth E, Dembinski JL, Dietrich M, Watson K, Klopp A, et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells. 2009;27(10):2614\u201323.","journal-title":"Stem Cells"},{"key":"4212_CR22","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3389\/fimmu.2020.01792","volume":"11","author":"B Blanco","year":"2020","unstructured":"Blanco B, Ram\u00edrez-Fern\u00e1ndez \u00c1, Alvarez-Vallina L. Engineering immune cells for in vivo secretion of tumor-specific t cell-redirecting bispecific antibodies. Front Immunol. 2020;11:1792.","journal-title":"Front Immunol"},{"issue":"12","key":"4212_CR23","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1517\/14712598.2010.531257","volume":"10","author":"TJ Myers","year":"2010","unstructured":"Myers TJ, Granero-Molto F, Longobardi L, Li T, Yan Y, Spagnoli A. Mesenchymal stem cells at the intersection of cell and gene therapy. Expert Opin Biol Ther. 2010;10(12):1663\u201379.","journal-title":"Expert Opin Biol Ther"},{"key":"4212_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.canlet.2017.05.003","volume":"402","author":"F Yan","year":"2017","unstructured":"Yan F, Li X, Li N, Zhang R, Wang Q, Ru Y, et al. Immunoproapoptotic molecule scFv-Fdt-tBid modified mesenchymal stem cells for prostate cancer dual-targeted therapy. Cancer Lett. 2017;402:32\u201342.","journal-title":"Cancer Lett"},{"issue":"1","key":"4212_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13045-017-0397-z","volume":"10","author":"X Zhang","year":"2017","unstructured":"Zhang X, Yang Y, Zhang L, Lu Y, Zhang Q, Fan D, et al. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3\/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor d-1-methyl-tryptophan. J Hematol OncolJ Hematol Oncol. 2017;10(1):56.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"12","key":"4212_CR26","doi-asserted-by":"publisher","first-page":"30015","DOI":"10.3390\/ijms161226215","volume":"16","author":"KJ Rhee","year":"2015","unstructured":"Rhee KJ, Lee J, Eom Y. Mesenchymal stem cell-mediated effects of tumor support or suppression. Int J Mol Sci. 2015;16(12):30015\u201333.","journal-title":"Int J Mol Sci"},{"key":"4212_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/scrt336","author":"A Ribeiro","year":"2013","unstructured":"Ribeiro A, Laranjeira P, Mendes S, Velada I, Leite C, Andrade P, et al. Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells. Stem Cell Res. 2013. https:\/\/doi.org\/10.1186\/scrt336.","journal-title":"Stem Cell Res"},{"issue":"1","key":"4212_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13046-019-1081-7","volume":"38","author":"W Zhong","year":"2019","unstructured":"Zhong W, Zhu Z, Xu X, Zhang H, Xiong H, Li Q, et al. Human bone marrow-derived mesenchymal stem cells promote the growth and drug-resistance of diffuse large B-cell lymphoma by secreting IL-6 and elevating IL-17A levels. J Exp Clin Cancer Res CR. 2019;38(1):73.","journal-title":"J Exp Clin Cancer Res CR"},{"issue":"12","key":"4212_CR29","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1089\/scd.2014.0254","volume":"24","author":"S Ciavarella","year":"2015","unstructured":"Ciavarella S, Caselli A, Tamma AV, Savonarola A, Loverro G, Paganelli R, et al. A peculiar molecular profile of umbilical cord-mesenchymal stromal cells drives their inhibitory effects on multiple myeloma cell growth and tumor progression. Stem Cells Dev. 2015;24(12):1457\u201370.","journal-title":"Stem Cells Dev"},{"issue":"1","key":"4212_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd.2016.193","volume":"16","author":"Y Shi","year":"2017","unstructured":"Shi Y, Du L, Lin L, Wang Y. Tumour-associated mesenchymal stem\/stromal cells: emerging therapeutic targets. Nat Rev Drug Discov. 2017;16(1):35\u201352.","journal-title":"Nat Rev Drug Discov"},{"key":"4212_CR31","unstructured":"Mesenchymal stem cell-mediated cancer therapy: A dual-targeted strategy of personalized medicine - PubMed [Internet]. [cited 2024 Nov 28]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22180830\/"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04212-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-025-04212-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04212-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T12:27:45Z","timestamp":1739363265000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-025-04212-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4212"],"URL":"https:\/\/doi.org\/10.1186\/s13287-025-04212-w","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments received approval from the ethical committee of Nanchang Medical College (Project title: Human mesenchymal stem cells as vehicles of tetravalent bispecific Tandab for the treatment of multiple myeloma combined with gamma-secretase inhibitors and its mechanism study; Approval number: NYLLSC20240701; Date of approval: 01\/07\/2024). Human MSCs, PBMC, and CD138+ BMMNCs were respectively isolated from umbilical cord, peripheral blood, and bone marrow with informed patient consent in accordance with the ethical committee of Jiangxi Provincial People\u2019s Hospital (Project title: Human mesenchymal stem cells as vehicles of tetravalent bispecific Tandab for the treatment of multiple myeloma combined with gamma-secretase inhibitors and its mechanism study; Approval number: 2024 (81); Date of approval: 11\/11\/2024).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}